# SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

> **NCT01752933** · PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** SGI-110

## Key facts

- **NCT ID:** NCT01752933
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01752933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01752933, "SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01752933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*